Tofacitinib for Sjögren syndrome with renal tubular acidosis and psoriasis

Li, Man; Liao, Pin‐Hsu; Xiang‐Zhang, Gui; Xin‐Xie, Yong; James, Wei Cheng‐Chung

doi:10.1111/1756-185x.14872

Cited by 1 publication

(1 citation statement)

References 5 publications

(8 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Rheumatoid arthritis (RA) is a chronic systemic inflammatory autoimmune disease that requires long-term treatment to suppress inflammation and prevent progressive joint damage. Two of the most commonly prescribed RA medications with differing mechanisms are tofacitinib and adalimumab (Zullow et al, 2014;Zubkov et al, 2021;Xu et al, 2022;Eqbal et al, 2023;Li et al, 2023). Tofacitinib is an oral small molecule Janus kinase (JAK) inhibitor that interferes with inflammatory cytokine signaling pathways (Zhu et al, 2021).…”

Section: Introductionmentioning

confidence: 99%

Risk of dyslipidemia and major adverse cardiac events with tofacitinib versus adalimumab in rheumatoid arthritis: a real-world cohort study from 7580 patients

Ma,

Shi,

Wang

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

ObjectiveTo compare the effects of tofacitinib and adalimumab on the risk of adverse lipidaemia outcomes in patients with newly diagnosed rheumatoid arthritis (RA).MethodsData of adult patients newly diagnosed with RA who were treated with tofacitinib or adalimumab at least twice during a 3-year period from 1 January 2018 to 31 December 2020, were enrolled in the TriNetX US Collaborative Network. Patient demographics, comorbidities, medications, and laboratory data were matched by propensity score at baseline. Outcome measurements include incidental risk of dyslipidemia, major adverse cardiac events (MACE) and all-cause mortality.ResultsA total of 7,580 newly diagnosed patients with RA (1998 receiving tofacitinib, 5,582 receiving adalimumab) were screened. After propensity score matching, the risk of dyslipidaemia outcomes were higher in the tofacitinib cohort, compared with adalimumab cohort (hazard ratio [HR] with 95% confidence interval [CI], 1.250 [1.076–1.453]). However, there is no statistically significant differences between two cohorts on MACE (HR, 0.995 [0.760–1.303]) and all-cause mortality (HR, 1.402 [0.887–2.215]).ConclusionTofacitinib use in patients with RA may increase the risk of dyslipidaemia to some extent compared to adalimumab. However, there is no differences on MACE and all-cause mortality.

show abstract